Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Dual HER2 blockade: preclinical and clinical data

  • 1, 2,
  • 1,
  • 1, 2,
  • 1, 2Email author,
  • 3 and
  • 3
Breast Cancer Research201416:468

https://doi.org/10.1186/s13058-014-0468-9

©  Patel et al.; licensee BioMed Central Ltd. 2014

  • Received: 20 August 2014
  • Accepted: 17 October 2014
  • Published:

The original article was published in Breast Cancer Research 2014 16:419

Abstract

No abstract.

Erratum

After publication of our review [1], we noted errors to the legend of Figure 1B, C. The ado-trastuzumab-emtansine concentration should be 1 μg/ml instead of 1 mg/ml. The trastuzumab concentration should be 10 μg/ml instead of 10 mg/ml. The lapatinib concentration should be 10 μM instead of 10 mM (Please see Figure 1, a corrected version of the original Figure 1).
Figure 1
Figure 1

Dual blockade with antibody–drug conjugate and targeted therapy. (A) SCID Beige mice were injected with 1 million cells per mouse in the estrogen receptor-positive, human epidermal growth factor receptor (HER)-positive cell line called BT474-m1. These animals were randomized into six groups and treated with: vehicle control; trastuzumab (5 mg/kg once weekly); lapatinib (100 mg/kg daily); ado-trastuzumab-emtansine (TDM-1; 5 mg/kg weekly); trastuzumab (5 mg/kg once weekly) + lapatinib (100 mg/kg daily); or TDM-1 (5 mg/kg weekly) + lapatinib (100 mg/kg daily). Tumor volume fold-change will be measured twice weekly post treatment. (B), (C) BT474 and SKBR3 HER2-positive cell lines were treated with the following: vehicle control; TDM-1 (1 μg/ml); trastuzumab (10 μg/ml) + lapatinib (10 μM) 4); or TDM-1 (1 μg/ml) + lapatinib (10 μM). Cells were assessed for proliferation and apoptosis post treatment. *Data analyzed by one way analysis of variance followed by Tukey analysis for a pairwise comparison of different groups, P < 0.05. T, trastuzumab; L, lapatinib. Data from J Chang, unpublished data.

Notes

Declarations

Authors’ Affiliations

(1)
Houston Methodist Cancer Center, 6445 Main Street, P21-34, Houston, 77030, TX, USA
(2)
Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, 10065, NY, USA
(3)
Division of Hemotology and Oncology, College of Medicine, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, 32224, FL, USA

References

  1. Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G: Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res. 2014, 16: 419-10.1186/s13058-014-0419-5.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Patel et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

Breast Cancer Research

ISSN: 1465-542X

Contact us